Navigation Links
Dr. Joel Posener Joins PharmaNet as Executive Medical Director, Neuroscience
Date:6/29/2011

PRINCETON, N.J., June 29, 2011 /PRNewswire/ -- PharmaNet Development Group, Inc., a leading provider of clinical development services to pharmaceutical, biotechnology, generic drug and medical device companies, announced today that Joel Posener, MD, has joined the Company as Executive Medical Director, Neuroscience. Dr. Posener will support PharmaNet project teams conducting clinical trials in psychiatry and neurology, and will provide drug development advice to clients in the area of neuroscience.

"We are thrilled Joel has joined PharmaNet," said Steven Leventer, PhD, Vice President and General Manager, Neuroscience. "His distinguished medical and clinical credentials will be a valuable addition to PharmaNet's experienced neuroscience team. Joel's appointment further demonstrates our commitment to help our clients develop innovative neuroscience therapeutics."

Dr. Posener obtained his medical degree from McGill University, completed a residency in psychiatry and fellowship in psychiatric research at Harvard Medical School and Massachusetts Mental Health Center, and is board certified in Psychiatry. Prior to joining PharmaNet, Dr. Posener held roles at Wyeth as Senior Director, Neuroscience Medical Research and Senior Director, Early Development and Clinical Pharmacology. He directed Phase II projects in a variety of psychiatric indications including cognitive impairment in schizophrenia, bipolar disorder and depression. Dr. Posener has also managed early clinical development programs in schizophrenia, depression and Alzheimer's disease.

Before joining the pharmaceutical industry, Dr. Posener served on the faculty of Harvard Medical School and Washington University School of Medicine in St. Louis, where he was also Medical Director of Metropolitan St. Louis Psychiatric Center, an academically affiliated public psychiatric hospital. He has published widely on mood disorders and related pathophysiogic processes. Dr. Posener currently holds an appointment as Clinical Associate Professor of Psychiatry at Temple University School of Medicine.

PharmaNet has conducted more than one hundred neuroscience clinical trials in the past five years. PharmaNet's success in neuroscience is the result of its therapeutically-aligned approach to serving our clients, in which available and informed senior neuroscience experts are integral members of project teams led by project managers and staffed by monitors with significant neuroscience experience. PharmaNet has conducted studies in virtually every area of psychiatry and neurology, all over the world.

About PharmaNet

PharmaNet Development Group, Inc., a recognized leader of global drug development services to the pharmaceutical, biotechnology, generic drug, and medical device industries, provides comprehensive capabilities in Phase I-IV clinical development, bioanalytical and bioequivalence services, regulatory, staffing, and therapeutic solutions. For the applied knowledge and intelligent solutions needed to accelerate drug development programs of all sizes around the world, PharmaNet works for you. For more information, please visit www.PharmaNet.com.

Contact:  Anne-Marie Hess
Phone:   (609) 951-6842
E-mail:   ahess@pharmanet.com


'/>"/>
SOURCE PharmaNet Development Group, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Eduard Alberts, Ph.D. Joins Sanford Rose Associates - San Francisco
2. Amicus Therapeutics Joins Russell 3000® Index
3. Dr. H. Daniel Perez Joins Celtaxsys Board of Directors
4. Governor Gray Davis Joins Genesis Biopharma as Chairman of Corporate Advisory Board
5. Matthias Spaenle, MD, Joins Oppenheimers Investment Banking Group as Managing Director - Healthcare
6. William T. Boehm Joins Neogens Board of Directors
7. Scott Garrett Joins Water Street Healthcare Partners
8. Sigma® Life Science Joins AMDeCs Vendor Partnership Program, Further Enhancing Value to Academic Medical Research Centers
9. Ed Weimer Joins Delta Point, Inc. as Executive Account Director
10. Former Capital One Director and Business Leader Stanley I. Westreich Joins Neuralstems Board
11. Former Cerner Chief Operating Officer Joins Netsmart Technologies Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... , June 23, 2016 Apellis ... Phase 1 clinical trials of its complement C3 ... single and multiple ascending dose studies designed to ... (PD) of subcutaneous injection in healthy adult volunteers. ... (SC) either as a single dose (ranging from ...
(Date:6/23/2016)... ... June 23, 2016 , ... Regulatory Compliance ... consulting, provides a free webinar on Performing Quality Investigations: Getting to ... 12pm CT at no charge. , Incomplete investigations are still a major concern ...
(Date:6/22/2016)... 22, 2016 Research and Markets has announced ... report to their offering. ... from $29.3 billion in 2013. The market is expected to grow ... 2015 to 2020, increasing from $50.6 billion in 2015 to $96.6 ... during the forecast period (2015 to 2020) are discussed. As well, ...
(Date:6/22/2016)... Washington, USA (PRWEB) , ... June 21, 2016 , ... ... and without cutting into the tissue — promise to enable both compact, wearable devices ... and from even deeper under the skin. , Recent work and visionary future directions ...
Breaking Biology Technology:
(Date:6/9/2016)... attendance control systems is proud to announce the introduction of fingerprint attendance control software, ... employees are actually signing in, and to even control the opening of doors. ... ... ... Photo - http://photos.prnewswire.com/prnh/20160609/377487 ...
(Date:6/3/2016)... 3, 2016 Das ... Nepal hat ein 44 ... geprägter Kennzeichen, einschließlich Personalisierung, Registrierung und IT-Infrastruktur, ... Produktion und Implementierung von Identitätsmanagementlösungen. Zahlreiche renommierte ... Januar teilgenommen, aber Decatur wurde als konformste ...
(Date:6/2/2016)... June 2, 2016 Perimeter Surveillance ... Unmanned Systems, Physical Infrastructure, Support & Other Service  ... visiongain offers comprehensive analysis of the global ... will generate revenues of $17.98 billion in 2016. ... Inc, a leader in software and hardware technologies for ...
Breaking Biology News(10 mins):